Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir

Liver International

Volumn 32, Issue 7, 2012, Pages 1179-1185

  Son, Chang Young ^a,b   Ryu, Han Jak ^a,b   Lee, Jung Min ^a,c   Ahn, Sang Hoon ^a,b,d   Kim, Do Young ^a,b   Lee, Myoung Ha ^a,b   Han, Kwang Hyub ^a,b,d   Chon, Chae Yoon ^a,b   Park, Jun Yong ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Liver Cirrhosis Clinical Research Center   (South Korea)

^c CHA University   (South Korea)

^d Brain Korea 21 Project for Medical Science   (South Korea)

Author keywords

(HBeAg positive) chronic hepatitis B; Adefovir; Entecavir; Lamivudine; Sequential therapy

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HEPATITIS B; HUMAN; MALE; MONOTHERAPY; PATIENT COMPLIANCE; PROGNOSIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADENINE; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GUANINE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 84863508763     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2012.02793.x     Document Type: Article

References (32)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
2. Chen C, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
3. Yuen M, Tanaka Y, Fong DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009; 50: 80-8.
4. Gish RG. Improving outcomes for patients with chronic hepatitis B. Curr Gastroenterol Rep 2007; 9: 14-22.
5. Lai C, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-96.
6. Lee JM, Park JY, Kim DY, et al. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Antivir Ther 2010; 15: 235-41.
7. Yim HJ, Hussain M, Liu Y, et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006; 44: 703-12.
8. Reijnders JG, Deterding K, Petersen J, et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010; 52: 493-500.
9. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-14.
10. Lee JM, Kim HJ, Park JY, et al. Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir. Antivir Ther 2009; 14: 705-12.
11. Sherman M, Yurdaydin C, Simsek H, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008; 48: 99-108.
12. Chang T, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
13. Gish RG, Lok AS, Chang T, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437-44.
14. Shim JH, Suh DJ, Kim KM, et al. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology 2009; 50: 1064-71.
15. Shin JW, Park NH, Jung SW, et al. Clinical usefulness of sequential hepatitis B virus DNA measurement (the roadmap concept) during adefovir treatment in lamivudine-resistant patients. Antivir Ther 2009; 14: 181-6.
16. Choe WH, Hong SP, Kim BK, et al. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir. Antivir Ther 2009; 14: 985-93.
17. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
18. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056-75.
19. Kim SU, Han K, Nam CM, et al. Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites. J Gastroenterol Hepatol 2008; 23: 1722-7.
20. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-83.
21. Ryu HJ, Lee JM, Ahn SH, et al. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. J Med Virol 2010; 82: 1835-42.
22. Brunelle M, Jacquard A, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41: 1391-8.
23. Reijnders JG, Pas SD, Schutten M, de Man RA, Janssen HL. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. J Hepatol 2009; 50: 674-83.
24. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307-13.
25. Lampertico P, Vigano M, Manenti E, et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133: 1445-51.
26. Inoue J, Ueno Y, Wakui Y, et al. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern. J Viral Hepat 2011; 18: 206-15.
27. Yuen M, Fung J, Wong DK, Lai C. Prevention and management of drug resistance for antihepatitis B treatment. Lancet Infect Dis 2009; 9: 256-64.
28. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5: 890-7.
29. Yuen M, Fung J, Seto W, et al. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy. Antivir Ther 2009; 14: 679-85.
30. Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004; 2: 266-72.
31. van Bmmel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51: 73-80.
32. Heo N, Lim Y, Lee HC, et al. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol 2010; 53: 449-54.